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Abstract
OBJECTIVE—To describe the epidemiology of extended-spectrum β-lactamase (ESBL)-
producing Escherichia coli (ESBL-EC) and Klebsiella pneumoniae (ESBL-KP) infections
DESIGN—Retrospective cohort
SETTING—Inpatient care at community hospitals
PATIENTS—All patients with ESBL-EC or ESBL-KP infections
METHODS—ESBL-EC and ESBL-KP infections from 26 community hospitals were 
prospectively entered into a centralized database from January 2009 to December 2014.
RESULTS—A total of 925 infections caused by ESBL-EC (10.5 infections per 100,000 patient 
days) and 463 infections caused by ESBL-KP (5.3 infections per 100,000 patient days) were 
identified during 8,791,243 patient days of surveillance. The incidence of ESBL-EC infections 
increased from 5.28 to 10.5 patients per 100,000 patient days during the study period (P =.006). 
The number of community hospitals with ESBL-EC infections increased from 17 (65%) in 2009 
to 20 (77%) in 2014. The median ESBL-EC infection rates among individual hospitals with ≥1 
ESBL-EC infection increased from 11.1 infections/100,000 patient days (range, 2.2–33.9 days) in 
2009 to 22.1 infections per 100,000 patient days (range, 0.66–134 days) in 2014 (P =.05). The 
incidence of ESBL-KP infections remained constant over the study period (P = .14). Community-
associated and healthcare-associated ESBL-EC infections trended upward (P =.006 and P = .02, 
respectively), while hospital-onset infections remained stable (P = .07). ESBL-EC infections were 
more common in females (54% vs 44%, P < .001) and Caucasians (50% vs 40%, P < .0001), and 
were more likely to be isolated from the urinary tract (61% vs 52%, P < .0001) than ESBL-KP 
infections.
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CONCLUSIONS—The incidence of ESBL-EC infection has increased in community hospitals 
throughout the southeastern United States, while the incidence of ESBL-KP infection has 
remained stable. Community- and healthcare-associated ESBL-EC infections are driving the 
upward trend.
Infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae 
are increasing worldwide. In some locations, including areas of Latin America, Europe, 
Asia, and Africa, ESBL-producing Enterobacteriaceae are endemic.1–6 In the United States, 
the incidence of infection with ESBL-producing Enterobacteriaceae at academic medical 
centers has increased during the past 9 years.7,8 Community acquisition of ESBL-producing 
Enterobacteriaceae infection appears to be responsible for a proportion of these 
infections,8,9 but data from community hospitals verifying this phenomenon are limited. 
Further data on the epidemiology of ESBL-producing Enterobacteriaceae in community 
hospitals are needed because more than half of the hospital care provided in the United 
States occurs in small, community hospitals.10
We previously reported on the emergence of ESBL-producing Escherichia coli (ESBL-EC) 
in a cohort of 16 community hospitals in North Carolina from 2005 to 2008.11 In the present 
study, we sought to understand how the incidence of ESBL-EC and ESBL-producing K. 
pneumoniae (ESBL-KP) infections has changed since 2009 in a larger cohort of community 
hospitals.
METHODS
Participating Hospitals and Study Patients
The Duke Infection Control Outreach Network (DICON) provides infection prevention and 
surveillance services to 43 community hospitals in the southeastern United States. Infection 
preventionists in DICON-affiliated hospitals routinely collect data on patients with ESBL-
producing bacterial isolates. These data are entered into a centralized, standardized database 
and include basic demographic information, date of hospital admission, previous admissions 
to the same hospital during the preceding year, specimen collection date and type, dialysis 
dependence, intensive care unit (ICU) admission, and whether admission is from home or 
another healthcare facility.
For the present study, we included data from 26 DICON-affiliated community hospitals in 
North Carolina (n = 20), Virginia (n =3), Georgia (n = 2), and South Carolina (n =1) with 
complete surveillance data during the 6-year study period.12 We excluded 17 community 
hospitals that either joined DICON after January 2009 or left the surveillance network 
before December 2014. The 26 study hospitals had a mean of 219 beds (range, 102–709 
beds) and were located in 25 different counties or independent cities. All patients with 
ESBL-producing organisms isolated from January 1, 2009 through December 31, 2014 
(study period) at these 26 hospitals were included. ESBL status was determined either by 
methods of the Clinical Laboratory Standards Institute or by automated platforms [ie, Vitek 
II (bioMérieux, Marcy-l’Étoile, France) or Microscan Walkaway (Dade Behring, Deerfield, 
IL, USA)] using panels provided by the manufacturer for this purpose. Specimen types were 
recorded for all patients. All analyses were performed using the first isolate for each patient.
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Standard definitions were used at all hospitals. Hospital-onset infection was defined by 
positive culture results of specimens collected >2 days after hospital admission. 
Community-onset infection was defined by positive culture results of specimens collected 
≤2 days after hospital admission. Community-onset infections were further classified as 
either healthcare-associated or community-associated.11 Patients with healthcare-associated 
infection had ≥1 of the following characteristics: home health care, admission from a 
nursing home or long-term care facility, transfer from another hospital, dependence on 
dialysis, or admission to a hospital within the previous 12 months. All other community-
onset infections were defined as community-associated infections. ICU requirement refers to 
whether a patient was in the ICU at the time of infection. Dialysis-dependence refers to 
whether a patient required dialysis at the time of admission. Patients with missing data were 
excluded from analyses requiring those data.
Statistical Analyses
We calculated incidence rates (number of new infections per 100,000 patient days per year) 
of infections due to ESBL-EC and ESBL-KP. Second, we compared the characteristics of 
patients infected with ESBL-EC with those of patients infected with ESBL-KP. Proportions 
were compared using the χ2 test, as appropriate. Poisson regression was used to determine 
trends in the rates of ESBL-EC and ESBL-KP detection and to calculate relative rates and 
95% confidence intervals (CI). Overdispersion was observed and corrected using the 
Pearson χ2 as the dispersion parameter. Generalized estimating equation (GEE) regression 
using a Poisson distribution was used to test for trend while controlling for nonrandom 
clustering of each outcome. Denominator data were normalized by log transformation. SAS 
version 9.3 software was used for all calculations (SAS Institute, Cary, NC). A 2-sided P 
value of ≤0.05 was considered significant for all tests.
RESULTS
We identified a total of 925 patients with ESBL-EC infection and 463 patients with ESBL-
KP infection during 8,791,243 patient days of surveillance. The aggregate rate of infection 
of ESBL-EC at the 26 study hospitals increased from 5.28 to 10.5 patients per 100,000 
patient days during the study period (P = .006) (Figure 1). In 2009, only 17 study hospitals 
(65%) had ≥1 patient with ESBL-EC infection; in 2014, 20 study hospitals (77%) had ≥1 
patient with ESBL-EC. Throughout the study period, 24 study hospitals (92%) had ≥1 
patient with ESBL-EC infection. The median ESBL-EC isolation rates among individual 
hospitals that had ≥1 ESBL-EC infection increased from 11.1/100,000 patient days (range, 
2.2–33.9) in 2009 to 22.1/100,000 patient days (range, 0.66–134) in 2014 (P = .05).
In contrast to the trend observed for ESBL-EC, the aggregate rate of ESBL-KP infection 
remained constant over the study period (P = .14) (Figure 1). In total, 23 study hospitals 
(88%) had ≥1 patient with ESBL-KP infection. There was no clear trend in the total number 
of hospitals with ESBL-KP infections throughout the study period, as 18 study hospitals 
(69%) had ≥1 ESBL-KP infection in 2009, and 20 (77%) had ≥1 ESBL-KP infection in 
2014. Of the 23 study hospitals with ≥1 ESBL-KP infection over the study period, the rate 
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of ESBL-KP isolation decreased or remained constant in 18 hospitals and increased in 5 
hospitals.
Patients with ESBL-EC infection were more likely to be female (500 of 925, 54%) than 
patients with ESBL-KP (203 of 463, 44%; P < .001) (Table 1). In addition, a larger 
percentage of ESBL-EC patients were Caucasian (50% vs 40%) and Hispanic (4% vs <1%). 
In contrast, a large proportion of ESBL-KP patients were African-American (35% vs 23%) 
(Table 1).
The overall distributions of hospital-onset, healthcare-associated, and community-associated 
infections were different between patients with ESBL-EC compared to ESBL-KP (P < .
0001, by 3 by 2 χ2 test) (Table 1). Patients with ESBL-EC were more likely to have 
community-associated infection than patients with ESBL-KP (23% vs 10%). In contrast, 
patients with ESBL-KP were more likely to have hospital-onset infection (17% vs 10%). 
The incidence of healthcare-associated and community-associated ESBL-EC infections 
increased significantly over the study period (P = .02 and P = .006, respectively), while the 
upward trend in hospital-onset infections did not reach statistical significance (P = .07) 
(Figure 2A). The incidence of corresponding ESBL-KP infections remained stable (Figure 
2B). Consistent with the fact that a greater proportion of ESBL-EC patients had community-
associated infections, ESBL-EC patients were more often admitted from home (57% vs 
48%). ESBL-KP patients were more often admitted from a nursing home or other extended-
care facility (45% vs 39%; P =.003; 8 × 2 χ2 test) (Table 1).
Patients with ESBL-EC and ESBL-KP infections had significantly different sources for their 
infections (P <.0001; 4 × 2 χ2 test) (Table 1). ESBL-EC and ESBL-KP patients were similar 
in proportion of bloodstream infections (16% vs 15%, respectively), but ESBL-EC were 
more often isolated from the urinary tract than ESBL-KP (61% vs 52%), and less often 
isolated from the sputum (4% vs 10%) (Table 1). Interestingly, a high proportion of all study 
patients were in the intensive care unit at the time of infection (ESBL-EC 14% and ESBL-
KP 20%; P =.02). Patients with ESBL-KP were more likely to be dialysis dependent (8%) 
than patients with ESBL-EC infections (5%, P = .01).
DISCUSSION
We previously demonstrated the emergence and rise in ESBL-EC infections in community 
hospitals from 2005 to 2008 in a cohort of 16 community hospitals in North Carolina.11 In 
this study, we described the continued increase in the rate of ESBL-EC infections in 26 
DICON community hospitals throughout the southeastern United States from 2009 to 2014 
and confirmed that ESBL-EC are more common than ESBL-KP. This increase was likely 
due to the increasing number of hospitals with ESBL-EC–infected patients and a general rise 
in the infection rate among hospitals with ESBL-EC infections throughout the study period. 
Of note, and importantly for clinicians, ESBL-EC infections were more likely to present as 
community-onset infections than ESBL-KP infections.
Our findings are consistent with a previous study that demonstrated a rising rate of 
community-associated ESBL infections in tertiary care hospitals.8 Our findings are novel, 
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however, because we identified this trend in small, community hospitals. This healthcare 
setting is particularly important; more than half of the healthcare in the United States is 
provided in this type of hospital.10 Given the small size of community hospitals and the 
generally low (though increasing) prevalence of ESBL-producing bacteria in the 
community, analysis of data collected in networks of community hospitals, or in large 
cohorts of hospitals that use similar laboratory and surveillance methods, are needed to fully 
understand the impact of ESBL-producing bacteria in the community.
Overall, the majority of infections caused by ESBL-EC occurred after healthcare exposure: 
>75% of ESBL-EC infections were either hospital onset or healthcare associated. Thus, we 
believe that hospitals, including both tertiary and community, and other healthcare facilities 
are important foci for ESBL transmission. Hospitalized patients have high13 and 
increasing14 levels of colonization with ESBL-producing bacteria, and patients in long-term 
care facilities are also frequently colonized.15 The lack of active screening for ESBL-
producing bacteria in the majority of American hospitals means that infection control 
measures such as contact isolation and patient cohorts are not applied to asymptomatic 
colonized patients. These “silently” colonized patients in turn increase the risk of 
transmission of highly resistant bacteria to susceptible patients via the hands of hospital staff 
or environmental contamination. Such “silent” intrahospital transmission predisposes 
hospitalized patients who become exposed and colonized to subsequent infections with 
ESBL-producing bacteria.14 The fact that most hospital- or healthcare-associated bacterial 
transmission events go unnoticed also means that the actual rate of ESBL-producing 
bacterial acquisition is much higher than our data suggest.
Remarkably, the increased rate of ESBL-EC infections noted in our study cohort occurred 
without a corresponding similar change in the rate of ESBL-KP infections. Including data 
from our prior analysis,11 our data demonstrate that the epidemiology of ESBL-KP 
remained largely unchanged from 2005 to 2014. Although the rate of ESBL-KP infections 
has increased in some geographic locations,16,17 other investigators have also described a 
trend of stable ESBL-KP infections and rising ESBL-EC infections similar to our findings in 
this study.8,18
The reasons for the disparity in ESBL-EC and ESBL-KP infection trends are unknown. 
However, this disparity could in part be related to higher rates of transmission of ESBL-EC 
outside healthcare settings. Only 10% of ESBL-KP infections in patients in our study were 
community associated. In contrast, 23% of patients with ESBL-EC infections were 
community associated, and there was a clear increasing trend in community-associated 
ESBL-EC infections over the study period. Other potential sources of ESBL-producing 
bacteria outside the healthcare system such as the food supply chain, water treatment and 
delivery systems, and soil may be responsible for the acquisition of both ESBL-EC and 
ESBL-KP by the patients in our study. Both ESBL-EC and ESBL-KP infections and 
colonization have been associated with each of these sources.19–28
The Clinical and Laboratory Standards Institute (CLSI) adopted new and lower minimum 
inhibitory concentration (MIC) breakpoints for aztreonam and several first- and third-
generation cephalosporins in 2010.29 We do not believe that these new breakpoints played a 
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major role in the increased ESBL-EC described here since we contacted all 26 hospitals and 
found that only 5 (19%) had adopted the lower MIC breakpoints over the study period. 
Furthermore, the 5 hospitals that did adopt the lower breakpoints made the transition in late 
2014 (ie, September–December). Therefore the observed increase in ESBL-EC infection 
incidence over the study period is not the result of shifting MIC guidelines.
A recent study by Chen et al30 demonstrated that 84% of ESBL-EC isolates from patients in 
community hospitals contain a CTX-M β-lactamase. We suspect that propagation of CTX-M 
β-lactamase genes is responsible in part for the increased rate of ESBL-EC infections we 
observed in our study population. Chen et al also reported that that 19% of infections by 
ESBL-producing bacteria were community associated.
We are aware of several limitations pertaining to this study. First, surveillance data were 
collected by local hospital infection preventionists following their interpretation of complex 
microbiology data. Despite use of standard protocols and database that serve to limit inter-
site variability, subjectivity is inherent in surveillance of this type. Second, all community 
hospitals in our cohort were located in the southeastern United States. Further study is 
needed to establish the generalizability of these findings to other geographic locations. 
Third, we did not collect data on the presence of particular ESBL enzyme variants; thus, we 
cannot comment on the molecular epidemiology of genes contributing to the ESBL 
phenotype in patients in our study. Fourth, we do not have complete data regarding the total 
number of admissions to participating hospitals over the study period. This information 
would be useful in further evaluating the incidence of healthcare-associated and community-
associated infections in particular. The limited hospital admission data demonstrate no 
trends toward increasing or decreasing admissions over time, however, which is consistent 
with the data regarding patient days. Therefore we feel that patient days is an appropriate 
denominator to evaluate trends in ESBL-EC and ESBL-KP infections. Despite these 
limitations, we believe our large, multicenter study provides a practical description of the 
detection rates of ESBL-EC and ESBL-KP in a sample of community hospitals, and 
highlights important epidemiological factors associated with their acquisition.
Further studies are needed to better understand the sources that are contributing to the 
growing reservoir of ESBL-EC within our communities. Our network serves as a regional 
surveillance resource for understanding the epidemiology of antimicrobial resistance in 
community hospitals that is analogous to the One-Health surveillance strategy recommended 
in the President’s National Action Plan to Combat Antibiotic-Resistant Bacteria, which 
emphasizes enhancement and expansion of existing surveillance networks in healthcare and 
community settings.31 DICON has more than tripled in size since its inception in 1998 to 43 
community hospitals throughout the southeastern United States presently; however, 
aggregated time-trended data from other regional surveillance networks in other geographic 
areas are needed to confirm these trends and to better understand the extent of ESBL-EC 
within our communities.
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Rate of extended-spectrum β-lactamase–producing E. coli (ESBL-EC) (A) and extended-
spectrum β-lactamase–producing K. pneumoniae (ESBL-KP) (B) infections in 26 
community hospitals throughout the southeastern United States by year. The mean rate of 
ESBL-EC and ESBL-KP infections per 100,000 patient days per year, along with the 95% 
confidence intervals (CI), are noted here. The trend lines and 95% CI were constructed using 
Poisson regression while controlling for clustering by hospital.
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Rate of extended-spectrum β-lactamase–producing E. coli (ESBL-EC) (A) and extended-
spectrum β-lactamase–producing K. pneumoniae (ESBL-KP) (B) infections in 26 
community hospitals throughout the southeastern United States by year, stratified by 
infection type. Infection types include hospital onset (HO), healthcare associated (HCA), 
and community associated (CA). The mean rate of ESBL-EC and ESBL-KP infections per 
100,000 patient days per year are noted here. Trend lines were constructed using Poisson 
regression while controlling for clustering by hospital.
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TABLE 1
Characteristics of Patients with ESBL-EC and ESBL-KP Infections in 26 Community Hospitals Throughout 
the Southeastern United States
ESBL-EC (N = 925), No. (%) ESBL-KP (N = 463), No. (%) P Value
Median age, y 72 (range, 0–100) 70 (range, 0–101) .96
Female gender 500 (54) 203 (44) <.001
Ethnicity
 Caucasian 466 (50) 183 (40) <.0001
 African-American 210 (23) 160 (35)
 Asian 10 (1) 1 (<1)
 Hispanic 35 (4) 2 (<1)
 Native American 4 (<1) 7 (2)
 Other/Unknown 200 (22) 110 (24)
Source
 Urinary tract 560 (61) 240 (52) <.0001
 Blood 150 (16) 70 (15)
 Sputum 36 (4) 47 (10)
 Other 179 (19) 106 (23)
Admission from
 Home 523 (57) 220 (48) .003
 Nursing home 320 (35) 180 (39)
 Home health 11 (1) 13 (3)
 Another hospital 10 (1) 13 (3)
 Other extended-care facility 33 (4) 26 (6)
 Hospice 4 (<1) 1 (<1)
 Newborn 2 (<1) 0 (0)
 Other/Unknown 22 (2) 10 (2)
Infection type
 Healthcare associated 610 (66) 333 (72) <.0001
 Community associated 216 (23) 47 (10)
 Hospital onset 94 (10) 80 (17)
ICU requirement 133 (14) 90 (19) .02
Dialysis dependent 44 (5) 38 (8) .01
NOTE. ESBL-EC; extended-spectrum β-lactamase-producing E. coli; ESBL-KP, extended-spectrum β-lactamase-producing K. pneumoniae; ICU, 
intensive care unit.
Infect Control Hosp Epidemiol. Author manuscript; available in PMC 2017 January 01.
